Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313618) titled 'Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1)' on Dec. 17, 2025.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Participant).

Primary Sponsor: West China Hospital

Condition: Oculocutaneous Albinism (OCA)

Intervention: Genetic: JWK010 gene therapy

Recruitment Status: Recruiting

Phase: Early Phase 1

Date of First Enrollment: December 22, 2025

Target Sample Size: 18

Countries of Recruitment: China

To know mor...